Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
NCT02562573Phase 2Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- May 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fezagepras in type 2 diabetes mellitus (T2DM), metabolic syndrome, sponsored by Liminal BioSciences Inc.. Started May 2015; status: completed.
02
Drugs
fezagepras
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic syndrome
Beyond the preview
Go deeper on NCT02562573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562573.